Fundz Deep Dive
Everything you need to win Tasca Therapeutics — in one platform.
Who to reach, what to say, and why now on Tasca Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Tasca Therapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Tasca Therapeutics Raises $52 Million with Co-leaders Cure and Regeneron Ventures
Dec 11, 2024•over 1 year ago
Contract Type
partnership
CambridgeBiotechnologyDescription
Tasca Therapeutics, a newly-minted small molecular inhibitor company, has raised $52 million in a Series A financing round. The round was co-led by Cure and Regeneron Ventures, with participation from Invus Group. The company plans to develop oncology drugs that target specific lipid-binding pockets on proteins.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months